Get the Stockscreener App
0.867
1.48%
-0.013
Pre-market:
.90
0.033
+3.81%
Oncolytics Biotech Inc stock is traded at $0.867, with a volume of 1.02M.
It is down -1.48% in the last 24 hours and down -6.53% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
See More
Previous Close:
$0.88
Open:
$0.89
24h Volume:
1.02M
Relative Volume:
0.87
Market Cap:
$103.48M
Revenue:
-
Net Income/Loss:
$-25.91M
P/E Ratio:
-3.4446
EPS:
-0.2517
Net Cash Flow:
$-22.73M
1W Performance:
-7.27%
1M Performance:
-6.53%
6M Performance:
-11.60%
1Y Performance:
+155.08%
1-Day Range:
$0.8507
$0.902
1-Week Range:
$0.8507
$1.18
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Name
Oncolytics Biotech Inc
Sector
Industry
Phone
(403) 670-7377
Address
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.867 | 105.03M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention - Yahoo Finance
Oncolytics Biotech (NASDAQ: ONCY) director Stephen Glover files initial Form 3 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director 30,000 options - Stock Titan
VersaFi ferme les marchés - Barchart.com
ONCOLYTICS BIOTECH (ONCY) CMO awarded 260,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options grant at $1.06 - Stock Titan
ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives stock options on 30,000 shares - Stock Titan
145,000 stock options granted to Oncolytics (ONCY) COO McAdory - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06 - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Why Oncolytics Biotech (ONCY) Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data - Sahm
Oncolytics Biotech Appoints Steve Glover to Board and Promotes John McAdory to COO - geneonline.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics appoints Glover to board, promotes McAdory to COO - Investing.com UK
Signs of Abundant Global Supplies Undercut Sugar Prices - Barchart.com
Wall Street May Still Be Looking at the Old Oncolytics Story - Barchart.com
Best Compounded Tirzepatide Online Provider (2026) Report Published by Kinross Research - Barchart.com
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - The IFP
Oncolytics appoints Glover to board, promotes McAdory to COO By Investing.com - Investing.com Canada
Oncolytics Biotech® Announces Appointment of Steve Glover - GlobeNewswire
Oncolytics (ONCY) Reports Promising Preclinical Study Results - GuruFocus
Oncolytics Biotech Reports Positive Preclinical Data for Pelareorep and RAS Inhibitor Combo in Solid Tumors - Minichart
Oncolytics Biotech (Nasdaq: ONCY) posts early pelareorep RAS-combo data - Stock Titan
Lab data show stronger RAS cancer combo; pancreatic, colorectal studies next - Stock Titan
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story - ACCESS Newswire
ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Analyst Jared Kelly Highlights Potential Opportunities for Oncolytics Biotech in Oncology Sector - geneonline.com
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com Australia
Oncolytics (ONCY) to Present Key Trial Data at 2026 ASCO Annual Meeting - GuruFocus
Oncolytics Biotech Reports New Clinical Data on Pelareorep for Pancreatic and Gastrointestinal Cancers in 2026 8-K Filing - Minichart
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (Nasdaq: ONCY) shows pelareorep immune activation data at ASCO 2026 - Stock Titan
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors - GlobeNewswire
New cancer immunotherapy linked to tumor volume drops at ASCO - Stock Titan
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Let - GuruFocus
ONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancer - MSN
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):